Seasonal Allergic Rhinitis (Hay Fever) Treatment
Covered by Aetna in California

Intranasal corticosteroid (INCS) as first-line for persistent or moderate-to-severe allergic rhinitis: fluticasone propionate 50mcg 2 sprays per nostril daily (or 1 spray per nostril twice daily); alternatively mometasone furoate 50mcg 2 sprays per nostril daily. Per 2026 ARIA-EAACI guidelines and historical AAAAI/ACAAI guidance, INCS monotherapy provides superior nasal symptom control (stuffiness, runny nose, sneezing) compared to oral antihistamines. For moderate-to-severe disease: azelastine-fluticasone combination spray (Dymista) — 1 spray per nostril twice daily — achieves faster onset and higher satisfaction than either component alone per 2026 ARIA-EAACI guidelines.

Oral second-generation antihistamines (OTC) for mild intermittent symptoms or eye symptoms: loratadine 10mg daily, cetirizine 10mg daily, fexofenadine 180mg daily — minimal sedation at standard doses. Intranasal antihistamine (azelastine 0.15% spray, 2 sprays per nostril twice daily) as monotherapy for mild-to-moderate disease with good fast-onset effect. Intranasal ipratropium 0.03% spray for isolated watery rhinorrhea unresponsive to other agents. Montelukast 10mg daily — weakly effective for allergic rhinitis; FDA 2020 boxed warning for neuropsychiatric effects (agitation, hallucinations, depression, suicidal ideation) limits enthusiasm. Oral decongestants (pseudoephedrine) for acute congestion; long-term intranasal decongestants are now contraindicated per 2026 ARIA guidelines due to rebound congestion risk with no added efficacy benefit over INCS.

Generic fluticasone propionate nasal spray: Tier 1, typically $10–$30. Generic mometasone nasal spray: Tier 1, typically $10–$25. Generic azelastine nasal spray: Tier 1–2, $15–$30. Montelukast generic: Tier 1, $4–$15. Combination azelastine-fluticasone (Dymista): Tier 3 branded, may require step therapy — PA typically required on some Aetna CA plans. Second-generation OTC antihistamines: not covered, $8–$15 OTC.

Montelukast carries a 2020 FDA boxed warning for serious neuropsychiatric effects including agitation, aggression, depression, hallucinations, insomnia, irritability, and suicidal thoughts — these can occur in children and adults, with or without prior psychiatric history. The FDA restricts montelukast use for allergic rhinitis to patients who have tried other therapies and determined them inadequate. TDMD reviews this risk explicitly before prescribing; patients with depression or anxiety history are not prescribed montelukast as first-line. Nasal polyps, unilateral nasal obstruction, anosmia, or symptoms unresponsive to maximal medical therapy warrant referral to ENT or allergy specialist for in-person evaluation and possible office-based intervention.

Aetna CA covers generic prescription intranasal corticosteroids (fluticasone propionate, mometasone, budesonide, triamcinolone) under the pharmacy benefit without mandatory step therapy through OTC options first — although some OTC versions now exist (fluticasone propionate OTC, triamcinolone OTC). If you've already tried OTC nasal spray without satisfactory results, Dr. Bhavsar can prescribe the prescription-strength formulation directly, which is covered at Tier 1 and often costs less than or similar to the OTC version after insurance. For combination azelastine-fluticasone (Dymista), some Aetna CA plans require prior authorization — if your plan requires step therapy, Dr. Bhavsar documents the clinical rationale for combination therapy to support authorization.

Yes, and this is a well-recognized phenomenon in California. Wildfire smoke particles (PM2.5 and PM10) irritate nasal and bronchial mucosa independently of allergen exposure, and the co-exposure to high pollen and heavy smoke — which often coincide in July through October — produces a compounded inflammatory response. Research has shown significantly increased respiratory and nasal symptom ED visits in California during high-smoke periods. During active wildfire smoke events (AQI >100, 'Unhealthy for Sensitive Groups' per CARB/AirNow): intensify your INCS use, add an oral antihistamine for systemic relief, keep windows closed and run an air purifier with HEPA filtration, and wear a properly fitted N95 when outdoors for extended periods. If your normal allergy medication regimen stops working during smoke season, a TDMD visit can address whether dose escalation, additional agents, or a short course of oral corticosteroids is warranted.

The concern is real and deserves honest discussion. The FDA added a boxed warning for montelukast in 2020 after accumulating reports of serious neuropsychiatric side effects — including agitation, aggression, anxiety, depression, hallucinations, suicidal ideation, and suicide — in both children and adults, with and without prior psychiatric history. For allergic rhinitis specifically (as opposed to asthma), the FDA now states montelukast should generally be reserved for patients who have not responded adequately to intranasal corticosteroids and antihistamines. Given that INCS sprays and second-generation antihistamines are highly effective with far safer side effect profiles, TDMD does not prescribe montelukast as first-line for allergic rhinitis. Patients with a personal or family history of depression, anxiety, or suicidal ideation are not prescribed montelukast. If you are currently on montelukast and experiencing mood changes, Dr. Bhavsar will evaluate whether discontinuation and transition to an INCS-based regimen is appropriate.

Yes. Aetna commercial plans cover telehealth visits for Seasonal Allergic Rhinitis (Hay Fever) in California. TeleDirectMD (Dr. Parth Bhavsar, MD, NPI: 1104323203) is an in-network telehealth provider with Aetna in California. Your standard Aetna telehealth copay applies — typically $10–$40 for most commercial plans. If clinically appropriate, your prescription is sent to your California pharmacy immediately after your visit.

Most Aetna commercial plans in California have telehealth copays of $10–$40. Often $0–$20 for employer plans. Your exact cost depends on your specific plan and whether your deductible has been met. Log into your Aetna member portal or call the member services number on your card to verify your telehealth copay before your seasonal allergies treatment visit. Self-pay is always available for a flat $49 if you prefer to skip insurance.

If your specific Aetna plan is not in-network with TeleDirectMD in California, or if your deductible has not yet been met, you can book as a self-pay patient for a flat $49 fee — same physician, same quality of care, no insurance needed. You may also be eligible to submit an out-of-network claim to Aetna for partial reimbursement depending on your plan's out-of-network benefit.

TeleDirectMD typically offers same-day and next-day video visits. Book at teledirectmd.com/book-online and select a time that works for you. Most patients are seen within a few hours of booking during business hours. Your seasonal allergies treatment symptoms are evaluated by Dr. Bhavsar, MD — not a nurse practitioner or PA — ensuring you receive a board-certified clinical assessment.

Yes. TeleDirectMD is operated by Dr. Parth Bhavsar, MD (NPI: 1104323203), a board-certified Family Medicine physician. TeleDirectMD is LegitScript certified, HIPAA compliant, and is contracted as an in-network telehealth provider with Aetna in California. Claims are billed using standard CPT codes (99213/99214) and submitted electronically to Aetna.

Yes. Telehealth visits with a licensed physician are qualified medical expenses eligible for FSA (Flexible Spending Account) and HSA (Health Savings Account) payment. If your Aetna plan applies your deductible first, your FSA or HSA card can be used to pay your portion. The $49 self-pay option is also FSA/HSA eligible.